This category focuses on antibodies engineered to remove or reduce fucose residues. It discusses production approaches, functional considerations, and uses in treatment.
Afucosylated antibodies boost ADCC by enhancing FcγRIIIa binding on NK cells. Biointron highlights their engineering, clinical approvals, and growing therapeutic applications.
Fc glycans regulate antibody activity. Biointron reviews their role in modulating immune function and therapeutic antibody efficacy.
Afucosylated antibodies enhance ADCC for stronger therapies. Biointron highlights their mechanism and clinical applications improving efficacy across treatments.
You can also contact us on the Scientist and Science Exchange marketplaces.
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
